{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:43:25Z","timestamp":1793479405972,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1136\/annrheumdis-2011-201117","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T04:50:32Z","timestamp":1339476632000},"page":"329-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"title":["Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis"],"prefix":"10.1016","volume":"72","author":[{"given":"John D","family":"Isaacs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley B","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyuan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2011-201117_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/ard.2010.135376","article-title":"The need for personalised medicine for rheumatoid arthritis.","volume":"70","author":"Isaacs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/ard.2010.148015","article-title":"Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response.","volume":"70","author":"Emery","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib3","article-title":"A personalized medicine approach to biological treatment of rheumatoid arthritis: a preliminary treatment algorithm","author":"Tak","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-201117_bib4","first-page":"S368","article-title":"Baseline autoantibody status (RF, ACPA) and clinical response following the first treatment course with rituximab","volume":"54","author":"Tak","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201117_bib5","first-page":"338","article-title":"Clinical response following the first treatment course with rituximab: effect of baseline autoantibody status (RF, ACPA)","volume":"66","author":"Tak","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","article-title":"Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.","volume":"68","author":"Potter","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib7","first-page":"S211","article-title":"Prediction of therapy response in anti-TNF\u03b1 treated RA patients based on the identification of biomarkers","volume":"58","author":"Drynda","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201117_bib8","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-201117_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib10","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201117_bib11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201117_bib12","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.30233","article-title":"B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201117_bib14","first-page":"911","article-title":"Rituximab therapy in Greek patients with rheumatoid arthritis.","volume":"2","author":"Tsiakalos","year":"2008","journal-title":"Biologics"},{"key":"10.1136\/annrheumdis-2011-201117_bib15","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib16","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).","volume":"49","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-201117_bib17","first-page":"442","article-title":"Autoantibody-positive rheumatoid arthritis patients have enhanced clinical response to rituximab when compared with seronegative patients","volume":"68","author":"Isaacs","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/rheumatology\/ken002","article-title":"Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.","volume":"47","author":"Kristensen","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-201117_bib19","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.","volume":"34","author":"Mancarella","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201117_bib20","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.","volume":"48","author":"Quartuccio","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-201117_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1136\/annrheumdis-2011-201117_bib22","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1136\/annrheumdis-2011-201117_bib23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1756-9966-30-114","article-title":"The Zfx gene is expressed in human gliomas and is important in the proliferation and apoptosis of the human malignant glioma cell line U251.","volume":"30","author":"Zhou","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1136\/annrheumdis-2011-201117_bib24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib25","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.1114465108","article-title":"Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.","volume":"108","author":"Shi","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/annrheumdis-2011-201117_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2006.060608","article-title":"High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.","volume":"66","author":"Bobbio-Pallavicini","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201117_bib27","first-page":"1067","article-title":"Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.","volume":"26","author":"Cuchacovich","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201117_bib28","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/rheumatology\/ker010","article-title":"The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.","volume":"50","author":"Klaasen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-201117_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3109\/s10165-010-0409-0","article-title":"In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.","volume":"21","author":"Kawashiri","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201117_bib30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724099783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724099783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2011-201117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T09:16:56Z","timestamp":1736068616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724099783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0003496724099783"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2011-201117","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2011-201117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}